Epizyme and Celgene scrap a PhI cancer trial; Inside the world of drug ads;

@FierceBiotech: Pfizer takes the lead in another hot immuno-oncology contest. Report | Follow @FierceBiotech

@JohnCFierce: Tick tock--Fierce 15 noms deadline is approaching. More | Follow @JohnCFierce

@DamianFierce: Probably the best thing about having lots of money is how it turns itself into even more money. Story | Follow @DamianFierce

> Epizyme ($EPZM) and partner Celgene ($CELG) are pulling the plug on a Phase I study of the cancer drug pinometostat after noting insufficient efficacy. The two are pressing forward with a pediatric study in leukemia and and plan to look into whether pinometostat can succeed as part of a combination therapy. News

> Despite the ongoing boom in valuations for young biotech companies, raising venture capital remains a daunting task, RaNA Therapeutics CEO Ron Renaud writes. More

> The Wall Street Journal takes a look at how some of the most ubiquitous TV drug ads get made. Story

Medical Device News

@FierceMedDev: Updated w/ info from $MDT: Medtronic recalls CoreValve TAVR component due to presence of particulate matter. Story | Follow @FierceMedDev

@VarunSaxena2: FDA issues warning on heart pump safety issues: strokes, blood clots and bleeding. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug. Story | Follow @EmilyWFierce

> TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report

> DexCom ups 2015 guidance but doesn't aim for profit; plans next-gen launches this year, in 2017. Story

> Cardinal scores $1B DOD contract as dealmaking delivers growth. Article

Pharma News

@FiercePharma: $GSK rehires former China government affairs director Shi. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: #FDA may add Baxter #saline Mexico plant to US supply. Now if Baxter can just quit having to recall saline. More | Follow @EricPFierce

@CarlyHFierce: What was summer before I covered takeover battles? | Follow @CarlyHFierce

> Actavis gets subpoena as DOJ probe of generic pricing moves up food chain. More

> Horizon has said it's ready to up its bid, Depomed CEO says. So where's the new offer? Article

> Biogen's Tecfidera faces new challenge as scientists call for monitoring for brain infections. News

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.